Literature DB >> 3567285

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.

J M Lachin, M A Foulkes.   

Abstract

When designing a clinical trial to test the equality of survival distributions for two treatment groups, the usual assumptions are exponential survival, uniform patient entry, full compliance, and censoring only administratively at the end of the trial. Various authors have presented methods for estimation of sample size or power under these assumptions, some of which allow for an R-year accrual period with T total years of study, T greater than R. The method of Lachin (1981, Controlled Clinical Trials 2, 93-113) is extended to allow for cases where patients enter the trial in a nonuniform manner over time, patients may exit from the trial due to loss to follow-up (other than administrative), other patients may continue follow-up although failing to comply with the treatment regimen, and a stratified analysis may be planned according to one or more prognostic covariates.

Entities:  

Mesh:

Year:  1986        PMID: 3567285

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  59 in total

1.  Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

Authors:  Pierre N Tariot; Lon S Schneider; Jeffrey Cummings; Ronald G Thomas; Rema Raman; Laura J Jakimovich; Rebekah Loy; Barbara Bartocci; Adam Fleisher; M Saleem Ismail; Anton Porsteinsson; Michael Weiner; Clifford R Jack; Leon Thal; Paul S Aisen
Journal:  Arch Gen Psychiatry       Date:  2011-08

2.  Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study.

Authors:  Donglin Zeng; Qingxia Chen; Ming-Hui Chen; Joseph G Ibrahim
Journal:  Biometrika       Date:  2011-12-29       Impact factor: 2.445

3.  Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model.

Authors:  John M Lachin
Journal:  Stat Med       Date:  2012-07-16       Impact factor: 2.373

4.  Special diabetes program for Indians: retention in cardiovascular risk reduction.

Authors:  Spero M Manson; Luohua Jiang; Lijing Zhang; Janette Beals; Kelly J Acton; Yvette Roubideaux
Journal:  Gerontologist       Date:  2011-06

5.  The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS).

Authors:  David B Matchar; Alan K Jacobson; Robert G Edson; Philip W Lavori; Jack E Ansell; Michael D Ezekowitz; Frederick Rickles; Lou Fiore; Kathy Boardman; Ciaran Phibbs; Stephan D Fihn; Julia E Vertrees; Rowena Dolor
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

6.  Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

Authors:  Srinivasan Dasarathy; Mack C Mitchell; Bruce Barton; Craig J McClain; Gyongyi Szabo; Laura E Nagy; Svetlana Radaeva; Arthur J McCullough
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

7.  Design of the Fracture Intervention Trial.

Authors:  D M Black; T F Reiss; M C Nevitt; J Cauley; D Karpf; S R Cummings
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

8.  Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma.

Authors:  Gautam Jha; Jeffrey S Miller; Julie M Curtsinger; Yan Zhang; Mathew F Mescher; Arkadiusz Z Dudek
Journal:  Am J Clin Oncol       Date:  2014-06       Impact factor: 2.339

9.  Sample size calculations for prevalent cohort designs.

Authors:  Hao Liu; Yu Shen; Jing Ning; Jing Qin
Journal:  Stat Methods Med Res       Date:  2016-07-11       Impact factor: 3.021

10.  Efficacy dilution in randomized placebo-controlled vaginal microbicide trials.

Authors:  Benoît R Mâsse; Marie-Claude Boily; Dobromir Dimitrov; Kamal Desai
Journal:  Emerg Themes Epidemiol       Date:  2009-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.